TransMed7
Private Company
Funding information not available
Overview
TransMed7 is a medical device innovator with a patented 'Zero5' forward-coring biopsy technology designed to overcome limitations of traditional side-cutting needles. Its platform enables single-insertion, multiple-collection biopsies with minimal tissue damage, targeting applications in breast health, lymph nodes, thyroid, and other soft tissues. The company is privately held, FDA-cleared for some devices, and operates with a philosophy of patient-first, globally accessible healthcare solutions. Its pipeline includes several handheld and stereotactic devices under brands like SpeedBird, Concorde, and Cardinal.
Technology Platform
Zero5 rotating beak, forward-coring biopsy technology enabling Single Insertion, Multiple Collection (SIMC) with minimal tissue damage and architectural preservation.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
TransMed7 competes in the crowded biopsy device market against giants like Hologic, BD, and Merit Medical, as well as other niche players. Its differentiation is based on its patented forward-coring Zero5 technology, which claims superior sample quality and procedural efficiency compared to traditional side-cutting needles.